Aripiprazole Treatment of the Prodrome

• Status: Terminated
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects. This study will explore how well Aripiprazole treats symptoms of early-onset psychotic disorders as well as symptoms that may indicate risk for such disorders, including unusual thoughts, suspiciousness, perceptual abnormalities, social isolation, and sudden changes in functioning.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwell Health
• Collaborator: Bristol-Myers Squibb
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

• You are between the ages of 13 and 22.

• You are English-speaking.

• You have a diagnosed psychotic disorder, including: schizophrenia, schizophreniform disorder, schizoaffective disorder, or other psychotic disorder

• OR -

• You are experiencing one or more pre-psychotic symptoms like unusual thoughts, suspiciousness, or unusual perceptual experiences.

• You meet additional RAP criteria assessed during screening and interview.

Exclusion Criteria:

• You have a diagnosis of bipolar disorder or major depression with psychotic features.

• You have a history of neurological, neuroendocrine, or other medical conditions known to affect the brain.

• You have past or current substance dependence.

• You are currently taking Aripiprazole.

• You have taken Aripiprazole in the past.

• You are currently taking and responding well to another medication.